Literature DB >> 29327977

Status and Challenges of Predicting and Diagnosing Sepsis in Burn Patients.

Mile Stanojcic1, Roohi Vinaik1, Marc G Jeschke1,2,3,4.   

Abstract

Burns are a common form of trauma that account for more than 300,000 deaths each year worldwide. Survival rates have improved over the past decades because of improvements in nutritional and fluid support, burn wound care, and infection control practices. Death, however, remains unacceptably high. The primary cause of death has changed over the last decades from anoxic causes to now predominantly infections and sepsis. Sepsis and septic complications are not only major contributors to poor outcomes, but they further result in longer hospital stay and higher healthcare costs. Despite the importance of infections and sepsis, the diagnosis and prediction remain a major challenge. To date, no clear diagnostic criteria or predictive formula exist that can predict reliably the occurrence of sepsis and infections. This review will highlight and discuss current definitions and criteria for diagnosis as well as predictive biomarkers of sepsis in patients with burns. It will also present the diagnostic tools employed, such as procalcitonin, C-reactive protein, and cytokines. We will discuss the benefits and shortcomings of different treatment modalities in the context of sepsis prevention. Last, we identify new therapeutic strategies for sepsis prediction and present future considerations to prevent sepsis in patients with burns. Minimizing and preventing septic complications through early detection would significantly benefit patients and necessitate continued research to unravel new biomarkers and mechanisms. Subsequent studies need to take a fresh perspective and consider the implementation of patient-centered therapeutic strategies.

Entities:  

Keywords:  biomarkers; burn sepsis; cytokines; diagnosis; infections

Mesh:

Substances:

Year:  2018        PMID: 29327977     DOI: 10.1089/sur.2017.288

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  7 in total

Review 1.  Management and prevention of drug resistant infections in burn patients.

Authors:  Roohi Vinaik; Dalia Barayan; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Expert Rev Anti Infect Ther       Date:  2019-08-04       Impact factor: 5.091

2.  The curative effect of Shenfu-injection in the treatment of burn sepsis and its effect on the patient's immune function, HMGB, and vWF.

Authors:  Chuanzhen Xu; Yongfu Xia; Zhuting Jia; Shasha Wang; Tongzhen Zhao; Liqiang Wu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 4.060

3.  The predictive role of Interleukin 6 in burn patients with positive blood cultures.

Authors:  Jochen Gille; Jovan Jocovic; Thomas Kremer; Armin Sablotzki
Journal:  Int J Burns Trauma       Date:  2021-04-15

4.  Stem cells derived from burned skin - The future of burn care.

Authors:  Saeid Amini-Nik; Reinhard Dolp; Gertraud Eylert; Andrea-Kaye Datu; Alexandra Parousis; Camille Blakeley; Marc G Jeschke
Journal:  EBioMedicine       Date:  2018-11-05       Impact factor: 8.143

5.  TNFR1, TNFR2, neutrophil gelatinase-associated lipocalin and heparin binding protein in identifying sepsis and predicting outcome in an intensive care cohort.

Authors:  Maria Bergquist; Line Samuelsson; Anders Larsson; Jonas Tydén; Joakim Johansson; Miklos Lipcsey
Journal:  Sci Rep       Date:  2020-09-18       Impact factor: 4.379

Review 6.  A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine.

Authors:  Anna Maria Azzini; Romolo Marco Dorizzi; Piersandro Sette; Marta Vecchi; Ilaria Coledan; Elda Righi; Evelina Tacconelli
Journal:  Ann Transl Med       Date:  2020-05

7.  Efficacy and safety of platelet-rich plasma in the treatment of severe burns: A protocol for systematic review and meta analysis.

Authors:  Zhao Chen; Yuyan Wu; Nurlan Turxun; Yingjie Shen; Xue Zhang
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.